AxoGen (NASDAQ:AXGN) Trading Down 4.8% – Should You Sell?

AxoGen, Inc. (NASDAQ:AXGN)’s share price traded down 4.8% on Tuesday . The company traded as low as $16.35 and last traded at $16.36. 77,254 shares were traded during trading, a decline of 80% from the average session volume of 390,326 shares. The stock had previously closed at $17.19.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, AxoGen currently has a consensus rating of “Buy” and an average target price of $15.00.

AxoGen Stock Down 5.4 %

The firm has a market capitalization of $715.60 million, a P/E ratio of -50.81 and a beta of 1.06. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The stock has a 50 day moving average of $14.05 and a 200-day moving average of $11.95.

Institutional Investors Weigh In On AxoGen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quest Partners LLC grew its position in shares of AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 2,076 shares in the last quarter. nVerses Capital LLC bought a new position in AxoGen in the 3rd quarter worth about $56,000. Koss Olinger Consulting LLC bought a new position in AxoGen in the 2nd quarter worth about $75,000. Oppenheimer & Co. Inc. purchased a new position in AxoGen during the 3rd quarter valued at about $156,000. Finally, Quantbot Technologies LP bought a new stake in shares of AxoGen during the third quarter valued at about $165,000. Institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.